Natera evaluates serial cfDNA blood testing in colon cancer

By staff writers

January 9, 2020 -- Cell-free DNA (cfDNA) testing company Natera is launching a study this year of its Signatera blood test in patients with stage II/III colorectal cancer to assess its value in molecular residual disease assessment and clinical outcomes.

The multicenter, registry study -- dubbed BESPOKE -- is slated to include 1,000 participants in the adjuvant setting. The protocol calls for serial testing in the months after surgery to provide information on several fronts, including whether adjuvant chemotherapy is needed, the likelihood and detection of relapse, and whether a curative treatment regimen is available based on individual characteristics.

The California-based company noted that Signatera has detected relapse in patients with stage II/III colorectal cancer up to 16.5 months earlier than other diagnostic tools, such as computed tomography (CT) scans and carcinoembryonic antigen (CEA) blood testing.

Natera said it expects to complete the study in 2023.

ACS finds colon cancer screening in 40s on the rise
Colon cancer screening among average-risk adults between the ages of 45 and 49 has been on the rise: It more than doubled in 2018, according to in-person...
ACP advises biennial -- not annual -- stool tests for colon cancer
In a debatable move, the American College of Physicians (ACP) advised biennial -- rather than annual -- testing of stool for signs of colorectal cancer...
ESMO: Blood test predicts relapse risk in colon cancer
A blood test showed potential for predicting relapse in nonmetastatic colon cancer patients and for reducing unnecessary treatments in a large study reported...
Foundation, Natera join to develop ctDNA assays
Foundation Medicine and Natera are joining forces to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays.
Natera touts liquid biopsy in bladder cancer
Results from Natera's prospective study validating its Signatera circulating tumor DNA (ctDNA) test in urothelial bladder cancer were published online...

Copyright © 2020

Last Updated np 1/9/2020 3:02:01 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.